Jazz Pharma (NASDAQ: JAZZ) director may sell 3,507 shares

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) received a Form 144 notice indicating that director Mark Douglas Smith may sell up to 3,507 shares of Jazz common stock through E*TRADE Financial Corporation. The securities information section lists an aggregate market value of $857,602.00 for these shares. The shares to be sold are tied to restricted stock vesting on 08/28/2026 and are shown as issued by the company as compensation. The filing also reports that during the prior three months, Smith sold 1,157 shares of common stock on 06/15/2026 for an aggregate sale price of $266,746.00.

Key Figures

Shares potentially to be sold: 3,507 shares of common stock Aggregate market value of shares covered: $857,602.00 Shares sold in prior 3 months: 1,157 shares of common stock +2 more

5 metrics

Shares potentially to be sold 3,507 shares of common stock Maximum number of Jazz Pharmaceuticals plc shares covered by the Form 144 notice

Aggregate market value of shares covered $857,602.00 Listed for the 3,507 Jazz Pharmaceuticals plc common shares in the securities information section

Shares sold in prior 3 months 1,157 shares of common stock Sale by Mark Douglas Smith on 06/15/2026 reported in the past 3 months section

Aggregate sale price of prior sale $266,746.00 Aggregate price for 1,157 shares sold on 06/15/2026

Restricted stock vesting date 08/28/2026 Date associated with restricted stock vesting for the 3,507 shares to be sold

Key Terms

Rule 144, restricted stock vesting, compensation, power of attorney

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"COMMON | 08/28/2026 | RESTRICTED STOCK VESTING | ISSUER"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

compensation financial

"3507 | 08/28/2026 | Compensation"

power of attorney regulatory

"Signature | /s/Paz Dizon by power of attorney for Mark D. Smith"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

What does the Form 144 filed for JAZZ disclose?

The Form 144 discloses that director Mark Douglas Smith may sell up to 3,507 shares of Jazz Pharmaceuticals plc (JAZZ) common stock under Rule 144, with an indicated aggregate market value of $857,602.00, related to restricted stock vesting on 08/28/2026.

How many JAZZ shares is Mark Douglas Smith planning to sell under this Form 144?

Mark Douglas Smith plans for a potential sale of up to 3,507 shares of Jazz Pharmaceuticals plc common stock, as reported in the Form 144 securities information and securities-to-be-sold sections.

What is the aggregate market value of the JAZZ shares covered by this Form 144?

The Form 144 lists an aggregate market value of $857,602.00 for the 3,507 shares of Jazz Pharmaceuticals plc common stock that may be sold under Rule 144.

What prior JAZZ stock sales by Mark Douglas Smith are reported in this Form 144?

The filing reports that on 06/15/2026, Mark Douglas Smith sold 1,157 shares of Jazz Pharmaceuticals plc common stock for an aggregate sale price of $266,746.00 during the prior three-month period.

What is the source of the JAZZ shares to be sold under this Form 144?

The Form 144 states that the 3,507 shares of JAZZ common stock are associated with restricted stock vesting on 08/28/2026, with the issuer shown as the source and the nature of acquisition described as Compensation.

Which broker is listed for the potential JAZZ share sale in this Form 144?

The broker listed is ETRADE Financial Corporation, associated with the potential sale of 3,507 shares of Jazz Pharmaceuticals plc common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 04:14 PM Accepted by SEC EDGAR 08/31/2026 - 04:14 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001756253
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Jazz Pharmaceuticals plc
SEC File Number	001-33500
Address of Issuer	FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD DUBLIN IRELAND D04 E5W7
Phone	353-1-634-7800
Name of Person for Whose Account the Securities are To Be Sold	Smith Mark Douglas
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	3507	857602.00	64914577	08/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/28/2026	RESTRICTED STOCK VESTING	ISSUER			3507	08/28/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SMITH MARK D. C/O Teladoc Health, Inc 2 Manhattanville Road, Ste 203 Purchase NY 10577	COMMON	06/15/2026	1157	266746.00

144: Remarks and Signature

Remarks
Date of Notice	08/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Paz Dizon by power of attorney for Mark D. Smith
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)